PREGABALIN: Package Insert and Label Information (Page 2 of 7)

5.5 Peripheral Edema

Pregabalin treatment may cause peripheral edema. In short-term trials of patients without clinically significant heart or peripheral vascular disease, there was no apparent association between peripheral edema and cardiovascular complications such as hypertension or congestive heart failure. Peripheral edema was not associated with laboratory changes suggestive of deterioration in renal or hepatic function.

In controlled clinical trials in adult patients, the incidence of peripheral edema was 6% in the pregabalin group compared with 2% in the placebo group. In controlled clinical trials, 0.5% of pregabalin patients and 0.2% placebo patients withdrew due to peripheral edema.

Higher frequencies of weight gain and peripheral edema were observed in patients taking both pregabalin and a thiazolidinedione antidiabetic agent compared to patients taking either drug alone. The majority of patients using thiazolidinedione antidiabetic agents in the overall safety database were participants in studies of pain associated with diabetic peripheral neuropathy. In this population, peripheral edema was reported in 3% (2/60) of patients who were using thiazolidinedione antidiabetic agents only, 8% (69/859) of patients who were treated with pregabalin only, and 19% (23/120) of patients who were on both pregabalin and thiazolidinedione antidiabetic agents. Similarly, weight gain was reported in 0% (0/60) of patients on thiazolidinediones only; 4% (35/859) of patients on pregabalin only; and 7.5% (9/120) of patients on both drugs.

As the thiazolidinedione class of antidiabetic drugs can cause weight gain and/or fluid retention, possibly exacerbating or leading to heart failure, exercise caution when co-administering pregabalin and these agents.

Because there are limited data on congestive heart failure patients with New York Heart Association (NYHA) Class III or IV cardiac status, exercise caution when using pregabalin in these patients.

5.6 Dizziness and Somnolence

Pregabalin may cause dizziness and somnolence. Inform patients that pregabalin-related dizziness and somnolence may impair their ability to perform tasks such as driving or operating machinery [see Patient Counseling Information (17)].

In the pregabalin controlled trials in adult patients, dizziness was experienced by 30% of pregabalin-treated patients compared to 8% of placebo-treated patients; somnolence was experienced by 23% of pregabalin-treated patients compared to 8% of placebo-treated patients. Dizziness and somnolence generally began shortly after the initiation of pregabalin therapy and occurred more frequently at higher doses. Dizziness and somnolence were the adverse reactions most frequently leading to withdrawal (4% each) from controlled studies. In pregabalin-treated patients reporting these adverse reactions in short-term, controlled studies, dizziness persisted until the last dose in 30% and somnolence persisted until the last dose in 42% of patients [see Drug Interactions (7)].
Pediatric use information is approved for Pfizer’s LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

5.7 Weight Gain

Pregabalin treatment may cause weight gain. In pregabalin controlled clinical trials in adult patients of up to 14 weeks, a gain of 7% or more over baseline weight was observed in 9% of pregabalin-treated patients and 2% of placebo-treated patients. Few patients treated with pregabalin (0.3%) withdrew from controlled trials due to weight gain. Pregabalin associated weight gain was related to dose and duration of exposure, but did not appear to be associated with baseline BMI, gender, or age. Weight gain was not limited to patients with edema [see Warnings and Precautions (5.5)].

Although weight gain was not associated with clinically important changes in blood pressure in short-term controlled studies, the long-term cardiovascular effects of pregabalin-associated weight gain are unknown.

Among diabetic patients, pregabalin-treated patients gained an average of 1.6 kg (range: -16 to 16 kg), compared to an average 0.3 kg (range: -10 to 9 kg) weight gain in placebo patients. In a cohort of 333 diabetic patients who received pregabalin for at least 2 years, the average weight gain was 5.2 kg.

While the effects of pregabalin-associated weight gain on glycemic control have not been systematically assessed, in controlled and longer-term open label clinical trials with diabetic patients, pregabalin treatment did not appear to be associated with loss of glycemic control (as measured by HbA1C ).

5.8 Tumorigenic Potential

In standard preclinical in vivo lifetime carcinogenicity studies of pregabalin, an unexpectedly high incidence of hemangiosarcoma was identified in two different strains of mice [see Nonclinical Toxicology (13.1)]. The clinical significance of this finding is unknown. Clinical experience during pregabalin’s premarketing development provides no direct means to assess its potential for inducing tumors in humans.

In clinical studies across various patient populations, comprising 6,396 patient-years of exposure in patients greater than 12 years of age, new or worsening-preexisting tumors were reported in 57 patients. Without knowledge of the background incidence and recurrence in similar populations not treated with pregabalin, it is impossible to know whether the incidence seen in these cohorts is or is not affected by treatment.

5.9 Ophthalmological Effects

In controlled studies in adult patients, a higher proportion of patients treated with pregabalin reported blurred vision (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing. Less than 1% of patients discontinued pregabalin treatment due to vision-related events (primarily blurred vision).

Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3,600 patients. In these patients, visual acuity was reduced in 7% of patients treated with pregabalin, and 5% of placebo-treated patients. Visual field changes were detected in 13% of pregabalin-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of pregabalin-treated and 2% of placebo-treated patients.

Although the clinical significance of the ophthalmologic findings is unknown, inform patients to notify their physician if changes in vision occur. If visual disturbance persists, consider further assessment. Consider more frequent assessment for patients who are already routinely monitored for ocular conditions [see Patient Counseling Information (17)].

5.10 Creatine Kinase Elevations

Pregabalin treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/L for pregabalin-treated patients and 28 U/L for the placebo patients. In all controlled trials in adult patients across multiple patient populations, 1.5% of patients on pregabalin and 0.7% of placebo patients had a value of creatine kinase at least three times the upper limit of normal. Three pregabalin-treated subjects had events reported as rhabdomyolysis in premarketing clinical trials. The relationship between these myopathy events and pregabalin is not completely understood because the cases had documented factors that may have caused or contributed to these events. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if these muscle symptoms are accompanied by malaise or fever. Discontinue treatment with pregabalin if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.

5.11 Decreased Platelet Count

Pregabalin treatment was associated with a decrease in platelet count. Pregabalin-treated subjects experienced a mean maximal decrease in platelet count of 20 × 103 /µL, compared to 11 × 103 /µL in placebo patients. In the overall database of controlled trials in adult patients, 2% of placebo patients and 3% of pregabalin patients experienced a potentially clinically significant decrease in platelets, defined as 20% below baseline value and less than 150 × 103 /µL. A single pregabalin-treated subject developed severe thrombocytopenia with a platelet count less than 20 × 103 / µL. In randomized controlled trials, pregabalin was not associated with an increase in bleeding-related adverse reactions.

5.12 PR Interval Prolongation

Pregabalin treatment was associated with PR interval prolongation. In analyses of clinical trial ECG data in adult patients, the mean PR interval increase was 3 to 6 msec at pregabalin doses greater than or equal to 300 mg/day. This mean change difference was not associated with an increased risk of PR increase greater than or equal to 25% from baseline, an increased percentage of subjects with on-treatment PR greater than 200 msec, or an increased risk of adverse reactions of second or third degree AV block.

Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications. However, these analyses cannot be considered definitive because of the limited number of patients in these categories.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:
• Angioedema [see Warnings and Precautions (5.1)]
• Hypersensitivity [see Warnings and Precautions (5.2 )]
• Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.3 )]
• Suicidal Behavior and Ideation [see Warnings and Precautions (5.4 )]
• Peripheral Edema [see Warnings and Precautions (5.5)]
• Dizziness and Somnolence [see Warnings and Precautions (5.6 )]
• Weight Gain [see Warnings and Precautions (5.7)]
• Tumorigenic Potential [see Warnings and Precautions (5.8)]
• Ophthalmological Effects [see Warnings and Precautions (5.9)]
• Creatine Kinase Elevations [see Warnings and Precautions (5.10)]
• Decreased Platelet Count [see Warnings and Precautions (5.11)]
• PR Interval Prolongation [see Warnings and Precautions (5.12 )]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In all controlled and uncontrolled trials across various patient populations during the premarketing development of pregabalin, more than 10,000 patients have received pregabalin. Approximately 5,000 patients were treated for 6 months or more, over 3,100 patients were treated for 1 year or longer, and over 1,400 patients were treated for at least 2 years.
Adverse Reactions Most Commonly Leading to Discontinuation in All Premarketing Controlled Clinical Studies
In premarketing controlled trials of all adult populations combined, 14% of patients treated with pregabalin and 7% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the adverse reactions most frequently leading to discontinuation were dizziness (4%) and somnolence (4%). In the placebo group, 1% of patients withdrew due to dizziness and less than 1% withdrew due to somnolence. Other adverse reactions that led to discontinuation from controlled trials more frequently in the pregabalin group compared to the placebo group were ataxia, confusion, asthenia, thinking abnormal, blurred vision, incoordination, and peripheral edema (1% each).
Most Common Adverse Reactions in All Controlled Clinical Studies in Adults
In premarketing controlled trials of all adult patient populations combined (including DPN, PHN, and adult patients with partial-onset seizures), dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and “thinking abnormal” (primarily difficulty with concentration/attention) were more commonly reported by subjects treated with pregabalin than by subjects treated with placebo (greater than or equal to 5% and twice the rate of that seen in placebo).
Controlled Studies with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Adverse Reactions Leading to Discontinuation
In clinical trials in adults with neuropathic pain associated with diabetic peripheral neuropathy, 9% of patients treated with pregabalin and 4% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (3%) and somnolence (2%). In comparison, less than 1% of placebo patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin group than in the placebo group, were asthenia, confusion, and peripheral edema. Each of these events led to withdrawal in approximately 1% of patients.
Most Common Adverse Reactions
Table 4 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 1% of patients with neuropathic pain associated with diabetic neuropathy in the combined pregabalin group for which the incidence was greater in this combined pregabalin group than in the placebo group. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”. Table 4. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Body system Preferred term

75 mg/day [N=77] %

150 mg/day [N=212] %

300 mg/day [N=321] %

600 mg/day [N=369] %

All PGB* [N=979] %

Placebo [N=459] %

Body as a whole

Asthenia

4

2

4

7

5

2

Accidental injury

5

2

2

6

4

3

Back pain

0

2

1

2

2

0

Chest pain

4

1

1

2

2

1

Face edema

0

1

1

2

1

0

Digestive system

Dry mouth

3

2

5

7

5

1

Constipation

0

2

4

6

4

2

Flatulence

3

0

2

3

2

1

Metabolic and nutritional disorders

Peripheral edema

4

6

9

12

9

2

Weight gain

0

4

4

6

4

0

Edema

0

2

4

2

2

0

Hypoglycemia

1

3

2

1

2

1

Nervous system

Dizziness

8

9

23

29

21

5

Somnolence

4

6

13

16

12

3

Neuropathy

9

2

2

5

4

3

Ataxia

6

1

2

4

3

1

Vertigo

1

2

2

4

3

1

Confusion

0

1

2

3

2

1

Euphoria

0

0

3

2

2

0

Incoordination

1

0

2

2

2

0

Thinking abnormal†

1

0

1

3

2

0

Tremor

1

1

1

2

1

0

Abnormal gait

1

0

1

3

1

0

Amnesia

3

1

0

2

1

0

Nervousness

0

1

1

1

1

0

Respiratory system

Dyspnea

3

0

2

2

2

1

Special senses

Blurry vision‡

3

1

3

6

4

2

Abnormal vision

1

0

1

1

1

0

* PGB: pregabalin
† Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking. ‡ Investigator term; summary level term is amblyopia

Controlled Studies in Postherpetic Neuralgia

Adverse Reactions Leading to Discontinuation

In clinical trials in adults with postherpetic neuralgia, 14% of patients treated with pregabalin and 7% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (4%) and somnolence (3%). In comparison, less than 1% of placebo patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring in greater frequency in the pregabalin group than in the placebo group, were confusion (2%), as well as peripheral edema, asthenia, ataxia, and abnormal gait (1% each).

Most Common Adverse Reactions

Table 5 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 1% of patients with neuropathic pain associated with postherpetic neuralgia in the combined pregabalin group for which the incidence was greater in this combined pregabalin group than in the placebo group. In addition, an event is included, even if the incidence in the all pregabalin group is not greater than in the placebo group, if the incidence of the event in the 600 mg/day group is more than twice that in the placebo group. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”. Overall, 12.4% of all pregabalin-treated patients and 9.0% of all placebo-treated patients had at least one severe event while 8% of pregabalin-treated patients and 4.3% of placebo-treated patients had at least one severe treatment-related adverse event.

Table 5. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia

Body system Preferred term

75 mg/d [N=84] %

150 mg/d [N=302] %

300 mg/d [N=312] %

600 mg/d [N=154] %

All PGB* [N=852] %

Placebo [N=398] %

Body as a whole

Infection

14

8

6

3

7

4

Headache

5

9

5

8

7

5

Pain

5

4

5

5

5

4

Accidental injury

4

3

3

5

3

2

Flu syndrome

1

2

2

1

2

1

Face edema

0

2

1

3

2

1

Digestive system

Dry mouth

7

7

6

15

8

3

Constipation

4

5

5

5

5

2

Flatulence

2

1

2

3

2

1

Vomiting

1

1

3

3

2

1

Metabolic and nutritional disorders

Peripheral edema

0

8

16

16

12

4

Weight gain

1

2

5

7

4

0

Edema

0

1

2

6

2

1

Musculoskeletal system

Myasthenia

1

1

1

1

1

0

Nervous system

Dizziness

11

18

31

37

26

9

Somnolence

8

12

18

25

16

5

Ataxia

1

2

5

9

5

1

Abnormal gait

0

2

4

8

4

1

Confusion

1

2

3

7

3

0

Thinking abnormal

0

2

1

6

2

2

Incoordination

2

2

1

3

2

0

Amnesia

0

1

1

4

2

0

Speech disorder

0

0

1

3

1

0

Respiratory system

Bronchitis

0

1

1

3

1

1

Special senses

Blurry vision

1

5

5

9

5

3

Diplopia

0

2

2

4

2

0

Abnormal vision

0

1

2

5

2

0

Eye Disorder

0

1

1

2

1

0

Urogenital System

Urinary Incontinence

0

1

1

2

1

0

* PGB: pregabalin

Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking.

Investigator term; summary level term is amblyopia
Controlled Studies of Adjunctive Therapy for Partial-Onset Seizures in Adult Patients
Adverse Reactions Leading to Discontinuation
Approximately 15% of patients receiving pregabalin and 6% of patients receiving placebo in trials of adjunctive therapy for partial-onset seizures discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the adverse reactions most frequently leading to discontinuation were dizziness (6%), ataxia (4%), and somnolence (3%). In comparison, less than 1% of patients in the placebo group withdrew due to each of these events. Other adverse reactions that led to discontinuation of at least 1% of patients in the pregabalin group and at least twice as frequently compared to the placebo group were asthenia, diplopia, blurred vision, thinking abnormal, nausea, tremor, vertigo, headache, and confusion (which each led to withdrawal in 2% or less of patients).

Most Common Adverse Reactions
Table 6 lists all dose-related adverse reactions occurring in at least 2% of all pregabalin-treated patients. Dose-relatedness was defined as the incidence of the adverse event in the 600 mg/day group was at least 2% greater than the rate in both the placebo and 150 mg/day groups. In these studies, 758 patients received pregabalin and 294 patients received placebo for up to 12 weeks. A majority of pregabalin-treated patients in clinical studies had adverse reactions with a maximum intensity of “mild” or “moderate”.Table 6. Dose-related Adverse Reaction Incidence in Controlled Trials of Adjunctive Therapy for Partial-Onset Seizures in Adult Patients

Body System Preferred Term

150 mg/d [N = 185] %

300 mg/d [N = 90] %

600 mg/d [N = 395] %

All PGB* [N = 670]† %

Placebo [N = 294] %

Body as a Whole

Accidental Injury

7

11

10

9

5

Pain

3

2

5

4

3

Digestive System

Increased Appetite

2

3

6

5

1

Dry Mouth

1

2

6

4

1

Constipation

1

1

7

4

2

Metabolic and Nutritional Disorders

Weight Gain

5

7

16

12

1

Peripheral Edema

3

3

6

5

2

Nervous System

Dizziness

18

31

38

32

11

Somnolence

11

18

28

22

11

Ataxia

6

10

20

15

4

Tremor

3

7

11

8

4

Thinking Abnormal‡

4

8

9

8

2

Amnesia

3

2

6

5

2

Speech Disorder

1

2

7

5

1

Incoordination

1

3

6

4

1

Abnormal Gait

1

3

5

4

0

Twitching

0

4

5

4

1

Confusion

1

2

5

4

2

Myoclonus

1

0

4

2

0

Special Senses

Blurred Vision§

5

8

12

10

4

Diplopia

5

7

12

9

4

Abnormal Vision

3

1

5

4

1

* PGB: pregabalin
† Excludes patients who received the 50 mg dose in Study E1.
‡ Thinking abnormal primarily consists of events related to difficulty with concentration/attention but also includes events related to cognition and language problems and slowed thinking.
§ Investigator term; summary level term is amblyopia.

Controlled Studies with Fibromyalgia

Adverse Reactions Leading to Discontinuation
In clinical trials of patients with fibromyalgia, 19% of patients treated with pregabalin (150 to 600 mg/day) and 10% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were dizziness (6%) and somnolence (3%). In comparison, less than 1% of placebo-treated patients withdrew due to dizziness and somnolence. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were fatigue, headache, balance disorder, and weight increased. Each of these adverse reactions led to withdrawal in approximately 1% of patients.

Most Common Adverse Reactions Table 9 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 2% of patients with fibromyalgia in the ‘all pregabalin’ treatment group for which the incidence was greater than in the placebo treatment group. A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of “mild” or “moderate”.

Table 9. Adverse Reaction Incidence in Controlled Trials in Fibromyalgia

System Organ Class Preferred term

150 mg/d [N=132] %

300 mg/d [N=502] %

450 mg/d [N=505] %

600 mg/d [N=378] %

All PGB* [N=1517] %

Placebo [N=505] %

Ear and Labyrinth Disorders

Vertigo

2

2

2

1

2

0

Eye Disorders

Vision blurred

8

7

7

12

8

1

Gastrointestinal Disorders

Dry mouth

7

6

9

9

8

2

Constipation

4

4

7

10

7

2

Vomiting

2

3

3

2

3

2

Flatulence

1

1

2

2

2

1

Abdominal distension

2

2

2

2

2

1

General Disorders and Administrative Site Conditions

Fatigue

5

7

6

8

7

4

Edema peripheral

5

5

6

9

6

2

Chest pain

2

1

1

2

2

1

Feeling abnormal

1

3

2

2

2

0

Edema

1

2

1

2

2

1

Feeling drunk

1

2

1

2

2

0

Infections and Infestations

Sinusitis

4

5

7

5

5

4

Investigations

Weight increased

8

10

10

14

11

2

Metabolism and Nutrition Disorders

Increased appetite

4

3

5

7

5

1

Fluid retention

2

3

3

2

2

1

Musculoskeletal and Connective Tissue Disorders

Arthralgia

4

3

3

6

4

2

Muscle spasms

2

4

4

4

4

2

Back pain

2

3

4

3

3

3

Nervous System Disorders

Dizziness

23

31

43

45

38

9

Somnolence

13

18

22

22

20

4

Headache

11

12

14

10

12

12

Disturbance in attention

4

4

6

6

5

1

Balance disorder

2

3

6

9

5

0

Memory impairment

1

3

4

4

3

0

Coordination abnormal

2

1

2

2

2

1

Hypoesthesia

2

2

3

2

2

1

Lethargy

2

2

1

2

2

0

Tremor

0

1

3

2

2

0

Psychiatric Disorders

Euphoric Mood

2

5

6

7

6

1

Confusional state

0

2

3

4

3

0

Anxiety

2

2

2

2

2

1

Disorientation

1

0

2

1

2

0

Depression

2

2

2

2

2

2

Respiratory, Thoracic and Mediastinal Disorders

Pharyngolaryngeal pain

2

1

3

3

2

2

* PGB: pregabalin
Controlled Studies in Neuropathic Pain Associated with Spinal Cord Injury

Adverse Reactions Leading to Discontinuation

In clinical trials of adults with neuropathic pain associated with spinal cord injury, 13% of patients treated with pregabalin and 10% of patients treated with placebo discontinued prematurely due to adverse reactions. In the pregabalin treatment group, the most common reasons for discontinuation due to adverse reactions were somnolence (3%) and edema (2%). In comparison, none of the placebo-treated patients withdrew due to somnolence and edema. Other reasons for discontinuation from the trials, occurring with greater frequency in the pregabalin treatment group than in the placebo treatment group, were fatigue and balance disorder. Each of these adverse reactions led to withdrawal in less than 2% of patients.

Most Common Adverse Reactions

Table 10 lists all adverse reactions, regardless of causality, occurring in greater than or equal to 2% of patients for which the incidence was greater than in the placebo treatment group with neuropathic pain associated with spinal cord injury in the controlled trials. A majority of pregabalin-treated patients in clinical studies experienced adverse reactions with a maximum intensity of “mild” or “moderate”.Table 10. Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Spinal Cord Injury

System Organ Class Preferred term

PGB* (N=182)

Placebo (N=174)

%

%

Ear and labryrinth disorders

Vertigo

2.7

1.1

Eye disorders

Vision blurred

6.6

1.1

Gastrointestinal disorders

Dry mouth

11.0

2.9

Constipation

8.2

5.7

Nausea

4.9

4.0

Vomiting

2.7

1.1

General disorders and administration site conditions

Fatigue

11.0

4.0

Edema peripheral

10.4

5.2

Edema

8.2

1.1

Pain

3.3

1.1

Infections and infestations

Nasopharyngitis

8.2

4.6

Investigations

Weight increased

3.3

1.1

Blood creatine phosphokinase increased

2.7

0

Musculoskeletal and connective tissue disorders

Muscular weakness

4.9

1.7

Pain in extremity

3.3

2.3

Neck pain

2.7

1.1

Back pain

2.2

1.7

Joint swelling

2.2

0

Nervous system disorders

Somnolence

35.7

11.5

Dizziness

20.9

6.9

Disturbance in attention

3.8

0

Memory impairment

3.3

1.1

Paresthesia

2.2

0.6

Psychiatric disorders

Insomnia

3.8

2.9

Euphoric mood

2.2

0.6

Renal and urinary disorders

Urinary incontinence

2.7

1.1

Skin and subcutaneous tissue disorders

Decubitus ulcer

2.7

1.1

Vascular disorders

Hypertension

2.2

1.1

Hypotension

2.2

0

* PGB: Pregabalin
Other Adverse Reactions Observed During the Clinical Studies of Pregabalin

Following is a list of treatment-emergent adverse reactions reported by patients treated with pregabalin during all clinical trials. The listing does not include those events already listed in the previous tables or elsewhere in labeling, those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life-threatening.

Events are categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse reactions are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients; rare reactions are those occurring in fewer than 1/1,000 patients. Events of major clinical importance are described in the Warnings and Precautions section (5).

Body as a Whole – Frequent: Abdominal pain, Allergic reaction, Fever, Infrequent: Abscess, Cellulitis, Chills, Malaise, Neck rigidity, Overdose, Pelvic pain, Photosensitivity reaction, Rare: Anaphylactoid reaction, Ascites, Granuloma, Hangover effect, Intentional Injury, Retroperitoneal Fibrosis, Shock

Cardiovascular System – Infrequent: Deep thrombophlebitis, Heart failure, Hypotension, Postural hypotension, Retinal vascular disorder, Syncope; Rare: ST Depressed, Ventricular Fibrillation

Digestive System – Frequent: Gastroenteritis, Increased appetite; Infrequent: Cholecystitis, Cholelithiasis, Colitis, Dysphagia, Esophagitis, Gastritis, Gastrointestinal hemorrhage, Melena, Mouth ulceration, Pancreatitis, Rectal hemorrhage, Tongue edema; Rare: Aphthous stomatitis, Esophageal Ulcer, Periodontal abscess

Hemic and Lymphatic System – Frequent: Ecchymosis; Infrequent: Anemia, Eosinophilia, Hypochromic anemia, Leukocytosis, Leukopenia, Lymphadenopathy, Thrombocytopenia; Rare: Myelofibrosis, Polycythemia, Prothrombin decreased, Purpura, Thrombocythemia, Alanine aminotransferase increased, Aspartate aminotransferase increased

Metabolic and Nutritional Disorders – Rare: Glucose Tolerance Decreased, Urate Crystalluria

Musculoskeletal System – Frequent: Arthralgia, Leg cramps, Myalgia, Myasthenia; Infrequent:
Arthrosis; Rare: Chondrodystrophy, Generalized Spasm

Nervous System – Frequent: Anxiety, Depersonalization, Hypertonia, Hypoesthesia, Libido decreased, Nystagmus, Paresthesia, Sedation, Stupor, Twitching; Infrequent: Abnormal dreams, Agitation, Apathy, Aphasia, Circumoral paresthesia, Dysarthria, Hallucinations, Hostility, Hyperalgesia, Hyperesthesia, Hyperkinesia, Hypokinesia, Hypotonia, Libido increased, Myoclonus, Neuralgia; Rare: Addiction, Cerebellar syndrome, Cogwheel rigidity, Coma, Delirium, Delusions, Dysautonomia, Dyskinesia, Dystonia, Encephalopathy, Extrapyramidal syndrome, Guillain-Barré syndrome, Hypalgesia, Intracranial hypertension, Manic reaction, Paranoid reaction, Peripheral neuritis, Personality disorder, Psychotic depression, Schizophrenic reaction, Sleep disorder, Torticollis, Trismus

Respiratory System – Rare: Apnea, Atelectasis, Bronchiolitis, Hiccup, Laryngismus, Lung edema, Lung fibrosis, Yawn

Skin and Appendages – Frequent: Pruritus, Infrequent: Alopecia, Dry skin, Eczema, Hirsutism, Skin ulcer, Urticaria, Vesiculobullous rash; Rare: Angioedema, Exfoliative dermatitis, Lichenoid dermatitis, Melanosis, Nail Disorder, Petechial rash, Purpuric rash, Pustular rash, Skin atrophy, Skin necrosis, Skin nodule, Stevens-Johnson syndrome, Subcutaneous nodule

Special senses – Frequent: Conjunctivitis, Diplopia, Otitis media, Tinnitus; Infrequent: Abnormality of accommodation, Blepharitis, Dry eyes, Eye hemorrhage, Hyperacusis, Photophobia, Retinal edema, Taste loss, Taste perversion; Rare: Anisocoria, Blindness, Corneal ulcer, Exophthalmos, Extraocular palsy, Iritis, Keratitis, Keratoconjunctivitis, Miosis, Mydriasis, Night blindness, Ophthalmoplegia, Optic atrophy, Papilledema, Parosmia, Ptosis, Uveitis

Urogenital System – Frequent: Anorgasmia, Impotence, Urinary frequency, Urinary incontinence; Infrequent: Abnormal ejaculation, Albuminuria, Amenorrhea, Dysmenorrhea, Dysuria, Hematuria, Kidney calculus, Leukorrhea, Menorrhagia, Metrorrhagia, Nephritis, Oliguria, Urinary retention, Urine abnormality; Rare: Acute kidney failure, Balanitis, Bladder Neoplasm, Cervicitis, Dyspareunia, Epididymitis, Female lactation, Glomerulitis, Ovarian disorder, Pyelonephritis

Comparison of Gender and Race

The overall adverse event profile of pregabalin was similar between women and men. There are insufficient data to support a statement regarding the distribution of adverse experience reports by race.

Pediatric use information is approved for Pfizer’s LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2020. All Rights Reserved.